

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all previous versions, and listings, of claims in the application.

1. **(Currently Amended)** A method for therapeutically treating a mammal bearing a tumor, the method comprising generating an immune response by administering to the mammal an effective amount of a therapeutic composition consisting essentially of an antibody or antigen binding fragment thereof that binds to an epitope of MUC-1, ~~said the epitope comprising a peptide and a carbohydrate, wherein the peptide comprises the amino acid sequence DTRPAP (SEQ ID NO:5), and wherein the antibody or antigen binding fragment thereof binds preferentially to glycosylated MUC-1 being an epitope to which a monoclonal antibody produced by a hybridoma that has ATCC Designation Number PTA-975 specifically binds.~~
2. **(Previously Presented)** The method of claim 1, wherein the antibody or fragment thereof that binds to an epitope of MUC-1 is non-radiolabeled.
- 3-4. **(Cancelled)**
5. **(Previously Presented)** The method of claim 1, wherein the immune response includes a T cell response.
6. **(Original)** The method of claim 1, wherein the mammal is a human.
7. **(Previously Presented)** The method of claim 1, wherein the therapeutic composition is administered intravenously.
8. **(Previously Presented)** The method of claim 1, wherein the therapeutic composition is administered subcutaneously.
9. **(Previously Presented)** The method of claim 1, wherein the antibody or antigen binding fragment thereof in the therapeutic composition is administered at a dosage of less than 8 mg / 30kg body weight.

10. **(Previously Presented)** The method of claim 1, wherein the antibody or antigen binding fragment in the therapeutic composition is administered at a dosage of less than 3 mg / 30kg body weight.

11. **(Previously Presented)** The method of claim 1, wherein the antibody or antigen binding fragment in the therapeutic composition is administered at a dosage of about 2 mg / patient.

12-15. **(Cancelled)**

16. **(Currently Amended)** A method for inducing the production of antibodies against a the multi-epitopic antigen MUC-1 comprising administering to the mammal an effective amount of a therapeutic composition consisting essentially of an antibody or antigen binding fragment thereof that specifically binds to a first epitope on the multi-epitopic antigen of MUC-1 such that the mammal generates an immune response comprising antibodies against a second epitope on the antigen of MUC-1, wherein the antigen is MUC-1 and the antibody or antigen binding fragment thereof in the composition binds to a first epitope is an epitope of MUC-1 of MUC-1 comprising a peptide and a carbohydrate, wherein the peptide comprises the amino acid sequence DTRPAP (SEQ ID NO:5), and wherein the antibody or antigen binding fragment thereof in the composition binds preferentially to glycosylated MUC-1 to which a monoclonal antibody produced by a hybridoma that has ATCC Designation Number PTA-975 specifically binds.

17. **(Previously Presented)** The method of claim 16, wherein the antibody or antigen binding fragment thereof is non-radiolabeled.

18. **(Currently Amended)** A method for therapeutically treating a mammal bearing a tumor comprising administering to the mammal an effective amount of a therapeutic composition consisting essentially of an antibody or antigen binding fragment thereof that specifically binds to a first epitope on the multi-epitopic antigen MUC-1 such that the mammal generates an immune response against a second epitope on the multi-epitopic antigen MUC-1, wherein the antibody or antigen binding fragment thereof in the composition binds to a first epitope of MUC-1 comprising a peptide and a carbohydrate, wherein the peptide comprises the amino acid

sequence DTRPAP (SEQ ID NO:5), wherein the antibody or antigen binding fragment thereof in the composition binds preferentially to glycosylated MUC-1, and wherein the antibody is not a monoclonal antibody selected from: HMPV, VU-3-C6, MF06, VU-11-D1, MF30, BCP8, DF3, BC2, B27.29, VU-3-D1, 7540MR, MF11, Bc4E549, VU-11-E2, M38, E29, GP1.4, 214D4, BC4W154, HMFG-2, HMFG-1, C595, Mc5 and A76-A/C7.

19-20. **(Cancelled)**

21. **(Previously Presented)** The method of claim 16 or 18, wherein the immune response includes a T cell response.

22. **(Previously Presented)** The method of claim 16 or 18, wherein the antibody is Alt-1.

23. **(Previously Presented)** The method of claim 16 or 18, wherein the mammal is a human.

24. **(Cancelled)**

25. **(Currently Amended)** The method of claim 16 or 18, wherein the ~~therapeutic~~ composition is administered intravenously.

26. **(Currently Amended)** The method of claim 16 or 18, wherein the ~~therapeutic~~ composition is administered subcutaneously.

27. **(Currently Amended)** The method of claim 16 or 18, wherein the antibody or antigen binding fragment thereof in the ~~therapeutic~~ composition is administered at a dosage of less than 8 mg / 30kg body weight.

28. **(Currently Amended)** The method of claim 16 or 18, wherein the antibody or antigen binding fragment thereof in the ~~therapeutic~~ composition is administered at a dosage of less than 3 mg / 30kg body weight.

29. **(Currently Amended)** The method of claim 16 or 18, wherein the antibody or antigen binding fragment thereof in the ~~therapeutic~~ composition is administered at a dosage of about 2 mg / patient.

30-41. **(Cancelled)**

42. **(Previously Presented)** The method of claim 16 or 18, wherein the antibody or antigen binding fragment thereof is selected from a monoclonal antibody, a chimeric antibody, a genetically engineered antibody, a Fab fragment, a F(ab')<sub>2</sub> fragment, and a single chain antibody.

43. **(Previously Presented)** The method of claim 1 wherein the antibody is Alt-1.

44.-46. **(Cancelled)**

47. **(Previously Presented)** The method of claim 18, wherein the antibody or antigen binding fragment thereof is non-radiolabeled.

48. **(Cancelled)**